Economic and patient-reported outcomes of oral triptans in the treatment of migraine

References

• Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N. Engl. J. Med. 346(4), 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Dueland AN, Leira R, Burke TA, Hillyer EV, Bolge S. The impact of migraine on work, family, and leisure among young women – a multinational study. Curr. Med. Res. Opin. 20(10), 1595–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 42(6), 501–509 (2002).
   PubMed Web of Science ®Google Scholar
• Burton WN, Conti DJ, Chen CY, Schultz AB, Edington DW. The economic burden of lost productivity due to migraine headache: a specific worksite analysis. J. Occup. Environ. Med. 44(6), 523–529 (2002).
   PubMed Web of Science ®Google Scholar
• Rasmussen BK. Epidemiology of headache. Cephalalgia 21(7), 774–777 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of healthcare use. Neurology 58(6), 885–894 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME. The epidemiology of migraine. Am. J. Med. 118(Suppl. 1), S3–S10 (2005).
   PubMedGoogle Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 45(Suppl. 1), S3–S13 (2005).
   Google Scholar
• Bigal ME, Lipton RB, Stewart WF. The epidemiology and impact of migraine. Curr. Neurol. Neurosci. Rep. 4(2), 98–104 (2004).
   PubMedGoogle Scholar
• Sadovsky R, Dodick DW. Identifying migraine in primary care settings. Am. J. Med. 118(Suppl. 1), S11–S17 (2005).
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch. Intern. Med. 159(8), 813–818 (1999).
   PubMed Web of Science ®Google Scholar
• Adelman JU, Adelman LC, Freeman MC, Von Seggern RL, Drake J. Cost considerations of acute migraine treatment. Headache 44(3), 271–285 (2004).
   PubMed Web of Science ®Google Scholar
• Badia X, Magaz S, Gutierrez L, Galvan J. The burden of migraine in Spain: beyond direct costs. PharmacoEconomics 22(9), 591–603 (2004).
   PubMed Web of Science ®Google Scholar
• Berg J. Economic evidence in migraine and other headaches: a review. Eur. J. Health Econ. 5(Suppl. 1), S43–S54 (2004).
   Google Scholar
• Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin. Ther. 23(1), 127–145 (2001).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Block G, Dahlof C et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 20(9), 765–786 (2000).
   PubMed Web of Science ®Google Scholar
• Pryse-Phillips WE, Dodick DW, Edmeads JG et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 156(9), 1273–1287 (1997).
   PubMed Web of Science ®Google Scholar
• Diamond ML. The role of concomitant headache types and non-headache co-morbidities in the underdiagnosis of migraine. Neurology 58(Suppl. 6), S3–S9 (2002).
   PubMed Web of Science ®Google Scholar
• Kaniecki RG. Migraine and tension-type headache: an assessment of challenges in diagnosis. Neurology 58(Suppl. 6), S15–S20 (2002).
   PubMed Web of Science ®Google Scholar
• Schreiber CP, Hutchinson S, Webster CJ, Ames M, Richardson MS, Powers C. Prevalence of migraine in patients with a history of self-reported or physician-diagnosed ‘sinus’ headache. Arch. Intern. Med. 164(16), 1769–1772 (2004).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55(6), 754–762 (2000).
   PubMed Web of Science ®Google Scholar
• Barrett B, Brown R, Mundt M et al. Using benefit harm tradeoffs to estimate sufficiently important difference: the case of the common cold. Med. Decis. Making 25(1), 47–55 (2005).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8), 633–658 (2002).
   PubMed Web of Science ®Google Scholar
• Geraud G, Olesen J, Pfaffenrath V et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 20(1), 30–38 (2000).
   PubMed Web of Science ®Google Scholar
• Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 97(3), 247–257 (2002).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3–9 (2002).
   PubMed Web of Science ®Google Scholar
• Cutrer FM, Goadsby PJ, Ferrari MD et al. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project). Clin. Ther. 26(9), 1533–1545 (2004).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol. Scand. 110(3), 137–143 (2004).
   PubMed Web of Science ®Google Scholar
• Couch JR Jr. Placebo effect and clinical trials in migraine therapy. Neuroepidemiology 6(4), 178–185 (1987).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. A triptan too far? J. Neurol. Neurosurg. Psychiatry 64(2), 143–147 (1998).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6), 1259–1287 (2000).
   PubMed Web of Science ®Google Scholar
• Bandolier. Migraine league table: acute treatments and 24 h sustained response, Bandolier Journal, (2005).
   Google Scholar
• Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 h. J. Manag. Care Pharm. 9(1), 45–52 (2003).
   PubMedGoogle Scholar
• Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 20(11), 1356–1364 (2000).
   PubMed Web of Science ®Google Scholar
• Caro G, Getsios D, Caro JJ, Raggio G, Burrows M, Black L. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 21(1), 12–19 (2001).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Raggio G, Caro G, Black L. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 41(5), 456–464 (2001).
   PubMed Web of Science ®Google Scholar
• Gross MLP, Dowson AJ, Deavey L, Duthie T. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. Br. J. Med. Econ. 10, 231–246 (1996).
   Google Scholar
• Wells N, Hettiarachchi J, Drummond M et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health. 6(4), 438–447 (2003).
   PubMed Web of Science ®Google Scholar
• Wang JT, Barr CE, Torigoe Y, Wang E, Rowland CR, Goldfarb SD. Cost savings in migraine associated with less chest pain on new triptan therapy. Am. J. Manag. Care 8(3 Suppl.), S102–S107 (2002).
   Web of Science ®Google Scholar
• Wang JT, Barr CE, Goldfarb SD. Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 42(Suppl. 1), 38–43 (2002).
   PubMedGoogle Scholar
• Mannix LK, Adelman JU, Goldfarb SD, Von S, Kozma CM. Almotriptan versus sumatriptan in migraine treatment: direct medical costs of managing adverse chest symptoms. Am. J. Manag. Care 8(3 Suppl.), S94–S101 (2002).
   Web of Science ®Google Scholar
• Litaker DG, Solomon GD, Genzen JR. Impact of sumatriptan on clinic utilization and costs of care in migraineurs. Headache 36(9), 538–541 (1996).
   PubMed Web of Science ®Google Scholar
• Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch. Intern. Med. 159(8), 857–863 (1999).
   PubMed Web of Science ®Google Scholar
• Lainez M. Clinical benefits of early triptan therapy for migraine. Cephalalgia 24(Suppl. 2), 24–30 (2004).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Lipton RB, Cady RK, Kwong WJ, Marlo KO, Batenhorst AS. Costs and outcomes of early versus delayed migraine treatment with sumatriptan. Headache 42(10), 984–999 (2002).
   PubMed Web of Science ®Google Scholar
• Cady RK, Sheftell F, Lipton RB, Kwong WJ, O’Quinn S. Economic implications of early treatment of migraine with sumatriptan tablets. Clin. Ther. 23(2), 284–291 (2001).
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Carides GW, Gerth WC, Santanello NC, Pigeon JG, Kramer. Work and productivity loss in the rizatriptan multiple attack study. Cephalalgia 20(9), 830–834 (2000).
   PubMed Web of Science ®Google Scholar
• Gerth WC, Sarma S, Hu XH, Silberstein SD. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J. Occup. Environ. Med. 46(1), 48–54 (2004).
   PubMed Web of Science ®Google Scholar
• Lofland JH, Kim SS, Batenhorst AS et al. Cost–effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin. Proc. 76(11), 1093–1101 (2001).
   PubMed Web of Science ®Google Scholar
• Williams P, Reeder CE. Cost–effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin. Ther. 25(11), 2903–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J. Manag. Care Pharm. 10(3), 259–265 (2004).
   PubMedGoogle Scholar
• Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am. J. Manag. Care 8(3 Suppl), S80–S84 (2002).
   Web of Science ®Google Scholar
• Belsey JD. Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Curr. Med. Res. Opin. 20(5), 659–669 (2004).
   PubMed Web of Science ®Google Scholar
• Mullins CD, Weis KA, Perfetto EM, Subedi PR, Healey PJ. Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. J. Manag. Care Pharm. 11(5), 394–402 (2005).
   PubMedGoogle Scholar
• Perfetto EM, Mullins CD, Subedi PR, Weis KA, Healey PJ. An economic evaluation of triptan products for migraine. Value Health 8(6), 647–655 (2005).
   Google Scholar
• Cates C. Triptan medications to treat acute migraine. Lancet 359(9312), 1152–1153 (2002).
   PubMedGoogle Scholar
• Dowson A, Kilminster S. Triptan medications to treat acute migraine. Lancet 359(9312), 1152–1153 (2002).
   PubMedGoogle Scholar
• Kernick DP. Triptan medications to treat acute migraine. Lancet 359(9312), 1152–1153 (2002).
   PubMedGoogle Scholar
• Palmer JB, Salonen R. Triptan medications to treat acute migraine. Lancet 359(9312), 1152–1153 (2002).
   Google Scholar
• Tfelt-Hansen P. Triptan medications to treat acute migraine. Lancet 359(9312), 1152–1153 (2002).
   PubMedGoogle Scholar
• Bussone G, Usai S, Grazzi L, Rigamonti A, Solari A, D’Amico D. Disability and quality of life in different primary headaches: results from Italian studies. Neurol. Sci. 25(Suppl. 3), S105–S107 (2004).
   PubMed Web of Science ®Google Scholar
• D’Amico D, Grazzi L, Usai S, Rigamonti A, Solari A, Bussone G. Measuring responses to therapy in headache patients. new and traditional end points. Neurol. Sci. 25(Suppl. 3), S108–S110 (2004).
   PubMed Web of Science ®Google Scholar
• Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 35(8), 449–454 (1995).
   PubMed Web of Science ®Google Scholar